Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Combination of two drugs shows promise in treating B-cell acute lymphoblastic leukemia

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be particularly difficult to treat in older patients, according to Cambridge scientists.

20 May 2025

Simple algorithm may help reduce treatment disparities in multiple sclerosis

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will be presented at the American Academy of Neurology's 77th Annual Meeting taking place April 5–9, 2025, in San Diego and online.

3 Mar 2025

Immunocompromised individuals need regular boosters for Covid-19 protection

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University of Cambridge has shown.

13 Feb 2025

Vaccinations alone may not protect immunocompromised patients, Cambridge research shows

13 Feb 2025

Updated guidelines for preventing and managing hepatitis B virus reactivation

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

27 Jan 2025

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs.

23 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

A new strategy for enhancing the production of protein-based drugs

An international team of researchers led by the University of California San Diego has developed a new strategy to enhance pharmaceutical production in Chinese hamster ovary (CHO) cells, which are commonly used to manufacture protein-based drugs for treating cancer, autoimmune diseases and much more.

15 Jan 2025

MS medications do not increase pregnancy risks, research shows

An analysis of over 3,700 pregnancies of women with multiple sclerosis indicates that the therapy doesn’t lead to increased risks of miscarriage, premature birth or serious birth defects.

18 Dec 2024

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.

11 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Rituximab News and Research

Navigating the dual role of B cells in tumor immunity

Combination of two drugs shows promise in treating B-cell acute lymphoblastic leukemia

Simple algorithm may help reduce treatment disparities in multiple sclerosis

Immunocompromised individuals need regular boosters for Covid-19 protection

Vaccinations alone may not protect immunocompromised patients, Cambridge research shows

Updated guidelines for preventing and managing hepatitis B virus reactivation

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new strategy for enhancing the production of protein-based drugs

MS medications do not increase pregnancy risks, research shows

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Novel drug combination shows promise for CLL treatment

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety

Emerging therapies transform autoimmune hepatitis treatment approaches

Research questions effectiveness of MS medications in slowing disability progression

Study reveals biomarkers that predict disability worsening in multiple sclerosis

Early intervention in pediatric-onset MS can lead to improved long-term outcomes

Review highlights mitochondrial dysfunction in cholestatic liver injury

New insights into stiff-person syndrome, advancing diagnosis and treatment

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News